Series B · Biotech
EpiBiologics: Series B
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...
Funding history
Series B · This round$107M
Loading rounds…
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...